Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 3/20 | 0.39 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322296 | 0.92 | HPRT1 (0.39) | HPRT1DNMT3AFGFR1SLC22A6ADORA2A | |
| SCHEMBL6322355 | 0.84 | HPRT1 (0.37) | HPRT1DNMT3AADORA2AADORA1 | |
| SCHEMBL6329654 | 0.84 | HPRT1 (0.37) | HPRT1DNMT3AADORA2AADORA1 | |
| SCHEMBL6321207 | 0.83 | HPRT1 (0.37) | HPRT1DNMT3AADORA2AADORA1 | |
| SCHEMBL6687661 | 0.82 | HPRT1 (0.48) | HPRT1FGFR1SLC22A6 | |
| SCHEMBL6324402 | 0.80 | HPRT1 (0.35) | HPRT1 | |
| SCHEMBL6324436 | 0.78 | FGFR1 (0.34) | HPRT1FGFR1SLC22A6 | |
| SCHEMBL6329303 | 0.77 | ADORA2A (0.46) | HPRT1DNMT3AFGFR1SLC22A6ADORA2A | |
| SCHEMBL6899488 | 0.77 | HPRT1 (0.47) | HPRT1FGFR1SLC22A6 | |
| SCHEMBL6904563 | 0.73 | HPRT1 (0.48) | HPRT1FGFR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080053-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | US | claimed |
| US-20050080053-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080053-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, RNASEH1 | HPRT1 680/4885DNMT3A 1071/4885FGFR1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.